Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NACDS offers platform for CPSIA certification

This article was originally published in The Tan Sheet

Executive Summary

Members of the National Association of Chain Drug Stores can access for free an online platform that allows for exchange of certificates of conformity with the Consumer Product Safety Improvement Act. The trade group and RollStream, a McLean, Va.-based software provider, announced Nov. 17 the launch of the Certificate Exchange Network. The platform allows retailers "to enter one site to obtain certificates for a large portion of the products they sell," an NACDS spokeswoman said in an e-mail. Manufacturers that already set up their own systems can link to certificates through the NACDS network, a RollStream spokeswoman said. Industry stakeholders recommended electronic certificates to comply with CPSIA, which the Consumer Product Safety Commission will enforce for packaging for iron-containing vitamins and other OTCs beginning Feb. 10, 2010 (1"The Tan Sheet" Oct. 12, 2009)

You may also be interested in...



Electronic CPSIA Packaging Certification Offers Key Benefits Over Paper

An electronic certification system will simplify compliance with the Consumer Product Safety Improvements Act of 2008 and likely will satisfy retailers demanding the certificates, experts say

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel